From the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.P.-C., H.S.C., M.W.F.).
Department of Physiology, University of Valencia and INCLIVA Biomedical Research Institute, Spain (D.P.-C.).
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):523-533. doi: 10.1161/ATVBAHA.119.312860. Epub 2020 Jan 2.
Peripheral artery disease, caused by chronic arterial occlusion of the lower extremities, affects over 200 million people worldwide. Peripheral artery disease can progress into critical limb ischemia (CLI), its more severe manifestation, which is associated with higher risk of limb amputation and cardiovascular death. Aiming to improve tissue perfusion, therapeutic angiogenesis held promise to improve ischemic limbs using delivery of growth factors but has not successfully translated into benefits for patients. Moreover, accumulating studies suggest that impaired downstream signaling of these growth factors (or angiogenic resistance) may significantly contribute to CLI, particularly under harsh environments, such as diabetes mellitus. Noncoding RNAs are essential regulators of gene expression that control a range of pathophysiologies relevant to CLI, including angiogenesis/arteriogenesis, hypoxia, inflammation, stem/progenitor cells, and diabetes mellitus. In this review, we summarize the role of noncoding RNAs, including microRNAs and long noncoding RNAs, as functional mediators or biomarkers in the pathophysiology of CLI. A better understanding of these ncRNAs in CLI may provide opportunities for new targets in the prevention, diagnosis, and therapeutic management of this disabling disease state.
外周动脉疾病是由下肢慢性动脉闭塞引起的,影响着全球超过 2 亿人。外周动脉疾病可进展为更严重的肢体缺血(CLI),其与更高的截肢和心血管死亡风险相关。为了改善组织灌注,治疗性血管生成通过输送生长因子来改善缺血肢体,但其并未成功转化为患者获益。此外,越来越多的研究表明,这些生长因子下游信号的受损(或血管生成抵抗)可能在外周动脉疾病中起重要作用,尤其是在糖尿病等恶劣环境下。非编码 RNA 是基因表达的重要调控因子,可调控与 CLI 相关的多种病理生理过程,包括血管生成/动脉生成、缺氧、炎症、干细胞/祖细胞和糖尿病。在这篇综述中,我们总结了非编码 RNA(包括 microRNA 和长非编码 RNA)作为 CLI 病理生理学中的功能调节剂或生物标志物的作用。更好地理解这些非编码 RNA 在 CLI 中的作用,可能为预防、诊断和治疗这种致残性疾病状态提供新的靶点。